^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Excerpt:
Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and lung cancer....While ERBB2-L755S and ERBB2-L755P mutants remained sensitive to AEE788 at very high concentrations (IC90 below 2 µM), the gatekeeper ERBB2-T798M mutation is totally resistant (IC50>2 µM) to AEE788 treatment...
DOI:
10.1371/journal.pone.0026760